Extended Data Fig. 10: Functional evaluation of KAT6B as a mediator of anthracycline response in breast cancer cells.
From: Chromatin regulators mediate anthracycline sensitivity in breast cancer
Panel A: RT-qPCR on cDNA showing inducible shRNA knockdown of KAT6B with 2 unique shRNA sequences in the HCC1954 breast cancer cell line. n=3 independent experiments. Center value equals mean +/- s.e.m. Panel B: Western blot on whole cell extract showing non-induced or induced knockdown shRNA KAT6B with no concomitant loss of drug targets TOP2A and TOP2B or gain in the drug efflux pump ABCB1; RNF2 as a loading control. Experiments were repeated independently three times with similar results. See Source Data 3. Panel C: Doxorubicin dose–response curves for KAT6B induced shRNAs (shRNA 2, 3) in HCC1954 cells and non-induced HCC1954 cells normalized to DMSO vehicle. Panel D: Etoposide dose–response curve for KAT6B induced shRNAs (shRNA 2, 3) in HCC1954 cells and non-induced HCC1954 cells normalized to DMSO vehicle. Panel E: Paclitaxel dose–response curve for KAT6B induced shRNAs (shRNA 2, 3) in HCC1954 cells and non-induced HCC1954 cells normalized to DMSO vehicle. n=4; 2 independent experiments of 2 independent shRNAs each for panels c-e. Center value is mean +/- s.e.m.
